Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 3,400 shares, a drop of 76.7% from the January 15th total of 14,600 shares. Based on an average daily volume of 14,800 shares, the short-interest ratio is presently 0.2 days.

Bavarian Nordic A/S Trading Down 2.2 %

Shares of BVNRY stock traded down $0.18 during trading hours on Friday, hitting $7.98. 31,045 shares of the company were exchanged, compared to its average volume of 8,568. The firm has a fifty day simple moving average of $8.82 and a 200 day simple moving average of $10.08. Bavarian Nordic A/S has a 52-week low of $6.86 and a 52-week high of $14.60. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 11.57 and a beta of 1.68.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.